Swapnil Potdar

1.1k total citations
40 papers, 538 citations indexed

About

Swapnil Potdar is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Swapnil Potdar has authored 40 papers receiving a total of 538 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 12 papers in Molecular Biology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Swapnil Potdar's work include Cancer Cells and Metastasis (8 papers), Cancer Genomics and Diagnostics (7 papers) and Acute Myeloid Leukemia Research (6 papers). Swapnil Potdar is often cited by papers focused on Cancer Cells and Metastasis (8 papers), Cancer Genomics and Diagnostics (7 papers) and Acute Myeloid Leukemia Research (6 papers). Swapnil Potdar collaborates with scholars based in Finland, Denmark and Sweden. Swapnil Potdar's co-authors include Krister Wennerberg, Jani Saarela, Tero Aittokallio, Aleksandr Ianevski, Olli Kallioniemi, Prson Gautam, Alexander Kononov, Anil K. Giri, Päivi Östling and John-Patrick Mpindi and has published in prestigious journals such as Nucleic Acids Research, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Swapnil Potdar

37 papers receiving 532 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Swapnil Potdar Finland 12 251 176 108 100 86 40 538
Disha Malani Finland 9 346 1.4× 88 0.5× 71 0.7× 101 1.0× 160 1.9× 15 531
Mika Kontro Finland 13 505 2.0× 156 0.9× 189 1.8× 142 1.4× 423 4.9× 53 903
Arvind Singh Mer Canada 11 311 1.2× 182 1.0× 24 0.2× 196 2.0× 55 0.6× 24 577
B. Hilda Ye United States 7 455 1.8× 149 0.8× 66 0.6× 102 1.0× 25 0.3× 14 692
Bhairavi Tolani United States 14 390 1.6× 226 1.3× 18 0.2× 123 1.2× 54 0.6× 18 743
Orsi Giricz United States 11 347 1.4× 172 1.0× 36 0.3× 125 1.3× 104 1.2× 23 567
Krysta Schlis United States 4 405 1.6× 182 1.0× 68 0.6× 67 0.7× 101 1.2× 6 625
Aleksandra Wroblewska Netherlands 12 255 1.0× 163 0.9× 42 0.4× 38 0.4× 205 2.4× 17 606
B. Belinda Ding United States 7 538 2.1× 273 1.6× 110 1.0× 148 1.5× 42 0.5× 11 1.0k
Chirayu Patel United States 8 331 1.3× 346 2.0× 35 0.3× 174 1.7× 86 1.0× 12 696

Countries citing papers authored by Swapnil Potdar

Since Specialization
Citations

This map shows the geographic impact of Swapnil Potdar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Swapnil Potdar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Swapnil Potdar more than expected).

Fields of papers citing papers by Swapnil Potdar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Swapnil Potdar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Swapnil Potdar. The network helps show where Swapnil Potdar may publish in the future.

Co-authorship network of co-authors of Swapnil Potdar

This figure shows the co-authorship network connecting the top 25 collaborators of Swapnil Potdar. A scholar is included among the top collaborators of Swapnil Potdar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Swapnil Potdar. Swapnil Potdar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mendiola, Marta, Jani Saarela, Victoria Heredia-Soto, et al.. (2024). Characterisation of new in vitro models and identification of potentially active drugs in angiosarcoma. Biomedicine & Pharmacotherapy. 173. 116397–116397. 1 indexed citations
2.
Kuivanen, Suvi, Swapnil Potdar, Antti Hassinen, et al.. (2024). Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome. Antiviral Research. 223. 105813–105813. 2 indexed citations
3.
Wang, Zhijia, А. Н. Бугай, Sergey G. Kuznetsov, et al.. (2023). P-TEFb promotes cell survival upon p53 activation by suppressing intrinsic apoptosis pathway. Nucleic Acids Research. 51(4). 1687–1706. 8 indexed citations
4.
Rizzo, Angela, Carmen Maresca, Carmen D’Angelo, et al.. (2023). Drug repositioning strategy for the identification of novel telomere‐damaging agents: A role for NAMPT inhibitors. Aging Cell. 22(11). e13944–e13944. 1 indexed citations
5.
Turunen, Laura, Antti Hassinen, Lauri Paasonen, et al.. (2023). Comparison of two supporting matrices for patient-derived cancer cells in 3D drug sensitivity and resistance testing assay (3D-DSRT). SLAS DISCOVERY. 28(4). 138–148. 8 indexed citations
6.
Potdar, Swapnil, Aleksandr Ianevski, Ziaurrehman Tanoli, et al.. (2023). Breeze 2.0: an interactive web-tool for visual analysis and comparison of drug response data. Nucleic Acids Research. 51(W1). W57–W61. 6 indexed citations
7.
Chen, Yingjia, Liye He, Aleksandr Ianevski, et al.. (2023). Robust scoring of selective drug responses for patient-tailored therapy selection. Nature Protocols. 19(1). 60–82. 5 indexed citations
8.
Banaei‐Esfahani, Amir, Hella Anna Bolck, Abdullah Kahraman, et al.. (2023). Ex Vivo Drug Testing in Patient-derived Papillary Renal Cancer Cells Reveals EGFR and the BCL2 Family as Therapeutic Targets. European Urology Focus. 9(5). 751–759. 6 indexed citations
9.
Heuser, Vanina D., Swapnil Potdar, Jaana Oikkonen, et al.. (2022). Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status. Frontiers in Oncology. 12. 954430–954430. 11 indexed citations
10.
Skaga, Erlend, Evgeny Kulesskiy, Swapnil Potdar, et al.. (2022). Functional temozolomide sensitivity testing of patient-specific glioblastoma stem cell cultures is predictive of clinical outcome. Translational Oncology. 26. 101535–101535. 3 indexed citations
11.
Arjama, Mariliina, Astrid Murumägi, Olli Kallioniemi, et al.. (2022). Protocol for 3D drug sensitivity and resistance testing of patient-derived cancer cells in 384-well plates. SLAS DISCOVERY. 28(2). 36–41. 3 indexed citations
12.
Kainulainen, Veera, et al.. (2022). Genome-wide siRNA screening reveals several host receptors for the binding of human gut commensal Bifidobacterium bifidum. npj Biofilms and Microbiomes. 8(1). 50–50. 1 indexed citations
13.
Mäyränpää, Mikko I., Swapnil Potdar, Jie Bao, et al.. (2021). Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments. Cell Reports Medicine. 2(8). 100373–100373. 3 indexed citations
14.
White, Brian S., Suleiman A. Khan, Muhammad Ammad-ud-din, et al.. (2021). Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. npj Precision Oncology. 5(1). 71–71. 16 indexed citations
15.
Hyytiäinen, Aini, Ahmed Al‐Samadi, Aleksandr Ianevski, et al.. (2021). High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma. Scientific Reports. 11(1). 14755–14755. 9 indexed citations
16.
Awad, Shady Adnan, Helena Hohtari, Komal Kumar Javarappa, et al.. (2020). Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets. Leukemia. 35(7). 1964–1975. 35 indexed citations
17.
Nagaraj, Ashwini S., Jennifer R. Devlin, Annabrita Hemmes, et al.. (2019). Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras -Mutant Lung Cancers. Molecular Cancer Therapeutics. 18(10). 1863–1874. 5 indexed citations
18.
Ianevski, Aleksandr, Anil K. Giri, Prson Gautam, et al.. (2019). Prediction of drug combination effects with a minimal set of experiments. Nature Machine Intelligence. 1(12). 568–577. 106 indexed citations
19.
Skaga, Erlend, Evgeny Kulesskiy, Cecilie Sandberg, et al.. (2019). Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma. BMC Cancer. 19(1). 628–628. 55 indexed citations
20.
Brodin, Bertha, Krister Wennerberg, Elisabet Lidbrink, et al.. (2019). Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas. British Journal of Cancer. 120(4). 435–443. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Disha Malani Breakdown of academic impact, for papers by Mika Kontro Breakdown of academic impact, for papers by Arvind Singh Mer Breakdown of academic impact, for papers by B. Hilda Ye Breakdown of academic impact, for papers by Bhairavi Tolani Breakdown of academic impact, for papers by Orsi Giricz Breakdown of academic impact, for papers by Krysta Schlis Breakdown of academic impact, for papers by Aleksandra Wroblewska Breakdown of academic impact, for papers by B. Belinda Ding Breakdown of academic impact, for papers by Chirayu Patel
Rankless by CCL
2026